| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050874318 |
| P356 | DOI | 10.1111/1523-1747.EP12329711 |
| P698 | PubMed publication ID | 8757769 |
| P2093 | author name string | A H Rook | |
| F P Gasparro | |||
| R Elenitsas | |||
| E K Yoo | |||
| B R Vowels | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| ultraviolet radiation | Q11391 | ||
| P304 | page(s) | 235-242 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action | |
| P478 | volume | 107 |
| Q36367784 | 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions |
| Q44403392 | 8-Methoxypsoralen and long-wave ultraviolet A inhibit the release of proinflammatory mediators and cytokines from human Fc epsilon RI+ cells: an in vitro study |
| Q38440874 | A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! |
| Q77796208 | Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis |
| Q44240094 | Apoptosis in leukocytes induced by UVA in the presence of 8-methoxypsoralen, chlorpromazine or 4,6,4'-trimethylangelicin |
| Q43956314 | Characteristics of photopheresis treatments for the management of rejection in heart and lung transplant recipients |
| Q36382986 | Chronic graft versus host disease of oral mucosa: review of available therapies |
| Q53949226 | Dendritic cells and apoptosis in mycosis fungoides. |
| Q76394119 | Differential response of linear and angular psoralens in PUVA-induced apoptosis in HL-60 cells |
| Q64089247 | Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease |
| Q82791974 | Evaluation of cell death after treatment with extracorporeal photopheresis |
| Q43620778 | Evaluation of the immunomodulatory mechanisms of photochemotherapy in transplantation |
| Q37798348 | Extra corporeal photo chemotherapy (ECP) in acute and chronic GVHD |
| Q89820696 | Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD) |
| Q44399135 | Extracorporeal Photopheresis in the Treatment of Persistent Rejection in a Pediatric Lung Transplant Recipient |
| Q37453628 | Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease |
| Q73202227 | Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens |
| Q33546975 | Extracorporeal photochemotherapy in human and murine graft-versus-host disease |
| Q92352895 | Extracorporeal photochemotherapy induces bona fide immunogenic cell death |
| Q34976053 | Extracorporeal photochemotherapy--the Columbia Presbyterian experience |
| Q73086625 | Extracorporeal photochemotherapy: a historical perspective |
| Q34135339 | Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD. |
| Q35050513 | Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment |
| Q34662907 | Extracorporeal photopheresis in chronic graft-versus-host disease |
| Q24187102 | Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q24200272 | Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q24202963 | Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q24187108 | Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q24200282 | Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q24200648 | Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients |
| Q52961199 | Extracorporeal photopheresis: Focus on therapeutic immunomodulation. |
| Q37467220 | Extracorporeal photopheresis: from solid organs to face transplantation |
| Q33726963 | Immunopathogenesis and therapy of cutaneous T cell lymphoma |
| Q24634395 | Immunotherapy of systemic sclerosis |
| Q80040589 | In vitro treatment of monocytes with 8-methoxypsolaren and ultraviolet A light induces dendritic cells with a tolerogenic phenotype |
| Q40607594 | Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy |
| Q43848117 | Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation |
| Q77211905 | Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis |
| Q35133357 | Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70 |
| Q35583232 | Management of the primary cutaneous lymphomas |
| Q35183850 | Mechanisms of action of extracorporeal photochemotherapy |
| Q35209490 | Mechanisms of action of extracorporeal photochemotherapy in the control of GVHD: involvement of dendritic cells |
| Q35200004 | Mechanisms of phototherapy and photochemotherapy for photodermatoses |
| Q44386087 | Medium-dose UV-A1 phototherapy. Successful treatment of cutaneous sarcoidosis |
| Q24793542 | New immunosuppressive drugs in heart transplantation |
| Q36932886 | Oral graft-versus-host disease. |
| Q34115974 | PUVA (psoralen + UVA) photochemotherapy: processes triggered in the cells |
| Q44348971 | PUVA apoptotic response in activated and resting human lymphocytes |
| Q33546971 | PUVA therapy: current concerns in Japan |
| Q44048956 | PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore |
| Q42161868 | Photochemotherapy induces the apoptosis of monocytes without impairing their function. |
| Q53955103 | Photopheresis affects the course of experimental allergic encephalomyelitis in Lewis rat. |
| Q28344648 | Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial |
| Q87422135 | Photopheresis up-regulates CD36 on monocytes and reduces CD25(+) and CD28(+) T cell numbers |
| Q35053428 | Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. |
| Q37979593 | Pruritus in cutaneous T-cell lymphoma: a review |
| Q35876581 | Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy |
| Q90405075 | Recent advances into the role of pattern recognition receptors in transplantation |
| Q37053020 | Serotonin signalling is crucial in the induction of PUVA-induced systemic suppression of delayed-type hypersensitivity but not local apoptosis or inflammation of the skin |
| Q43426810 | Steroid refractory psoriasiform cutaneous graft versus host disease successfully treated by extracorporeal photopheresis: a case report |
| Q74471722 | Successful monotherapy of severe and intractable atopic dermatitis by photopheresis |
| Q36498959 | Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? |
| Q42507006 | The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD). |
| Q44850844 | The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease |
| Q37962159 | The role of the extracorporeal photopheresis in the management of the graft-versus-host disease |
| Q35612038 | The treatment of cutaneous T-cell lymphoma with photopheresis |
| Q77361528 | Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy |
| Q34748813 | Transimmunization, a novel approach for tumor immunotherapy |
| Q73119374 | Treatment of cutaneous T cell lymphoma with extracorporeal photopheresis induces Fas-ligand expression on treated T cells, but does not suppress the expression of co-stimulatory molecules on monocytes |
| Q73202188 | Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis) |
| Q53928589 | Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. |
| Q33690110 | Update on immunoelectron microscopy in diagnostic dermatopathology and cutaneous biology |
| Q37955511 | Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children |
| Q38212474 | Updating ECP action mechanisms |
| Q84471693 | [Extracorporeal photopheresis in dermatology] |
| Q43970148 | p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells |
Search more.